Possible Alzheimer's disease in an apolipoprotein E2 homozygote

Journal of Alzheimer's Disease

Volumn 16, Issue 1, 2009, Pages 35-38

  Ignatov, Ignat ^a   Belden, Christine ^a   Jacobson, Sandra ^a   Connor, Donald ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E2; Homozygote; PET scan

Indexed keywords

APOLIPOPROTEIN E2; DONEPEZIL; LEVOTHYROXINE; MEMANTINE; MULTIVITAMIN; PARACETAMOL; PREDNISONE; ROPINIROLE; SERTRALINE; TRAZODONE;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN ATROPHY; BRAIN HEMORRHAGE; BRAIN INFARCTION; BREAST CANCER; CASE REPORT; CONFUSION; DEMENTIA; DEPRESSION; DISEASE COURSE; DISORIENTATION; FEMALE; FIBROMYALGIA; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENOTYPE; HERPES ZOSTER; HOMOZYGOTE; HUMAN; HYSTERECTOMY; KYPHOSIS; LEARNING; MASTECTOMY; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULAR RASH; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPRIOCEPTION; RESTLESS LEGS SYNDROME; VIBRATION; VISUAL MEMORY;

EID: 58849096632     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0932     Document Type: Article

References (20)

1. Mahley RW (1988) Apolipoprotein E:cholesterol transport protein with expanding role in cell biology, Science 240 622-630.
2. Strittmatter WJ, Roses AD (1995) Apolipoprotein E, Alzheimer's disease, Proc Natl Acad Sci USA 92 4725-4727.
3. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease, Nat Genet 7 180-184.
4. Lippa CF, Smith TW, Saunders AM, Hullete C, Pulaski-Salo D, Roses AD (1997) Apolipoprotein E-epsilon 2 and Alzheimer's disease:genotype influences pathologic phenotype, Neurology 148 515-519.
5. Berlau DJ, Kahle-Wrobleski K, Head E, Goodus M, Kim R, Kawas C (2007) Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E 2/2 genotype, Arch Neurol 64 1193-1196.
6. Folstein MF, Folstein SE, McHugh PR (1975) Mini -mental state, J Psychiatric Res 12 189-198.
7. Reisberg B (1988) Functional Assessment Staging (FAST) Psychopharmacol Bull 24 653-659.
8. Wechsler Abbreviated Scale of Intelligence (WASI) (1999) Psychological Corporation, San Antonio.
9. Delis DC, Kaplan E, Kramer JH, Ober BA (2000) California Verbal Learning Test-Second Edition (CVLTII) Manual, Psychological Corporation, San Antonio.
10. Wechsler D (1987) Wechsler Memory Scale-Revised: Manual, The Psychological Corporation, San Antonio.
11. Army Individual Test Battery (1944) Manual of Directions and Scoring, War Department, Adjutant General's Office, Washington, DC.
12. Kaplan E, Goodglass H, Weintraub S (2001) Boston Naming Test-Second Edition (BNT-2), Lippincott Williams & Wilkins, Baltimore.
13. Royall DR, Mahurin RK, Gray KF (1992) Bedside assessment of executive cognitive impairment: the executive interview, J Am Geriatr Soc 40 1221-1226.
14. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short orientation-memory-concentration test of cognitive impairment, Am J Psychiatry 140 734-739.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 939-944.
16. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thai LJ, Corey-Bloom J (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease, Neurology 62 1977-1983.
17. Love S, Siew LK, Dawbarn D, Wilcock GK, Ben-Shlomo Y, Allen SJ (2006) Premorbid effects of APOE on synaptic proteins in human temporal neocortex, Neurobiol Aging 27 797-803.
18. Miyata M, Smith JD, Apolipoprotein E allele-specific antioxdant activity and effects on cytotoxicity by oxidative insultsand beta-amyloid peptides, Nat Genet 14, 55-61.
19. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome, JAMA 286 2120-2127.
20. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons, Neurology 69 2197-2204.